Related Experiment Video
Updated: Aug 16, 2026

Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE
Published on: July 29, 2014
Down-regulation of p53 by double-stranded RNA modulates the antiviral response
Joao T Marques1, Dominique Rebouillat, Chilakamarti V Ramana
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA.
Abstract:
p53 has been well characterized as a tumor suppressor gene, but its role in antiviral defense remains unclear. A recent report has demonstrated that p53 can be induced by interferons and is activated after vesicular stomatitis virus (VSV) infection. We observed that different nononcogenic viruses, including encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulation of p53 in infected cells. Double-stranded RNA (dsRNA) and a mutant vaccinia virus lacking the dsRNA binding protein E3L can also induce this effect, indicating that dsRNA formed during viral infection is likely the trigger for down-regulation of p53. The mechanism of down-regulation of p53 by dsRNA relies on translation inhibition mediated by the PKR and RNase L pathways. In the absence of p53, the replication of both EMCV and HPIV3 was retarded, whereas, conversely, VSV replication was enhanced. Cell cycle analysis indicated that wild-type (WT) but not p53 knockout (KO) fibroblasts undergo an early-G(1) arrest following dsRNA treatment. Moreover, in WT cells the onset of dsRNA-induced apoptosis begins after p53 levels are down-regulated, whereas p53 KO cells, which lack the early-G(1) arrest, rapidly undergo apoptosis. Hence, our data suggest that the down-regulation of p53 facilitates apoptosis, thereby limiting viral replication.
Insights
Viral infection down-regulates the tumor suppressor p53, which is crucial for triggering apoptosis and limiting viral replication. This process involves double-stranded RNA and PKR/RNase L pathways.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- The tumor suppressor p53's role in antiviral defense is not fully understood.
- Previous studies suggest p53 activation by interferons and vesicular stomatitis virus (VSV).
- However, other viruses like encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3) induce p53 down-regulation.
Purpose of the Study:
- To investigate the role of p53 in antiviral defense.
- To elucidate the mechanism by which viral infection affects p53 levels.
- To determine the impact of p53 down-regulation on viral replication and host cell fate.
Main Methods:
- Induction of p53 down-regulation using non-oncogenic viruses (EMCV, HPIV3) and double-stranded RNA (dsRNA) mimics.
- Utilizing a mutant vaccinia virus lacking the E3L protein to study dsRNA's role.
- Assessing viral replication in wild-type (WT) and p53 knockout (KO) cells.
- Performing cell cycle analysis and apoptosis assays following dsRNA treatment.
Main Results:
- Viral infection and dsRNA trigger p53 down-regulation via PKR and RNase L mediated translation inhibition.
- p53 down-regulation enhances VSV replication but retards EMCV and HPIV3 replication.
- WT cells exhibit an early-G1 arrest upon dsRNA treatment, while p53 KO cells do not.
- Apoptosis is initiated in WT cells after p53 down-regulation, whereas p53 KO cells undergo rapid apoptosis.
Conclusions:
- p53 down-regulation by viral dsRNA is a key mechanism in antiviral response.
- This down-regulation facilitates apoptosis, which is essential for limiting viral replication.
- The interplay between p53, apoptosis, and viral replication highlights a novel aspect of tumor suppressor function in immunity.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Abnormal Proliferation
Experimental RNAi

